Chronic prostatitis/chronic pelvic pain syndrome: Interplay of inflammatory mediators, "Beyond the Abstract," by Dan Lundh, Hans Hedelin, and Dennis Larsson ...

Previously presented at ESMO 2023, 177 Lu-PSMA-617 prolonged radiographic progression-free survival versus change of androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC in PSMAfore ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Comparing GreenLight PVP and HoLEP Beyond 5 Years: A Systematic Review of Long-Term Functional Outcomes and Reoperation Rates - Beyond the Abstract ...

Alicia Morgans sits down with Charles Ryan to discuss the recent publication of Urologic Oncology: Multidisciplinary Care for Patients, a book she co-edited with Kelly Stratton. Nicolas Mottet, MD, Ph ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Amy Pearlman discusses penile rehabilitation strategies following prostate cancer treatment. Dr. Pearlman shares her expertise on vacuum pump therapy as a crucial component of penile rehabilitation.

(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting featured an oral abstract session on urothelial carcinoma, and a presentation by Dr. Daniel Petrylak discussing the ...

AUA 2025 trial protocol of CORE-008, intravesical cretostimogene grenadenorepvec, non-muscle invasive bladder cancer (NMIBC), RB-E2F alterations.

Read the Full Video Transcript Rashid Sayyid: Hello, everyone, and thank you for joining us today in this UroToday recording. I'm Rashid Sayyid, robotic urology and oncology fellow at USC, and I'm ...

SUO 2025 high-risk non-muscle invasive bladder cancer (HR-NMIBC), carcinoma in situ (CIS), AQUA Registry, intravesical chemotherapy.

ASCO 2024 results of CORE-001, cretostimogene grenadenorepvec in combination with pembrolizumab, in patients with BCG-unresponsive non-muscle invasive bladder cancer with CIS.